Cholecalciferol injection BP 600000 IU/2 ML Specification
Packaging Type
5*2ml AMP
Life Span
24 Month
Salt Composition
Cholecalciferol injection BP 600000 IU/2 ML
Brand Name
Calciark D3
Drug Type
Injection
Ingredients
Cholecalciferol Injection BP 600,000 IU/2 mL is a high-potency intramuscular vitamin D3 (cholecalciferol) solution in a 2 mL ampoule for rapid correction of severe vitamin D deficiency.
Vitamin D3 promotes intestinal calcium/phosphorus absorption, bone mineralization, and immune modulation, treating nutritional osteomalacia, rickets, osteoporosis, hypocalcemia, and chronic kidney disease-related mineral bone disorder; single high-dose replenishes stores lasting 4-6 months.
Physical Form
Liquid
Quantity
1 Unit
Storage Instructions
cool & dry place
Cholecalciferol injection BP 600000 IU/2 ML Trade Information
Minimum Order Quantity
100 Pieces
Supply Ability
500 Pieces Per Month
Delivery Time
5 Days
About Cholecalciferol injection BP 600000 IU/2 ML
Cholecalciferol Injection BP 600,000 IU/2 mL is a sterile, oily intramuscular solution of vitamin D3 (cholecalciferol) providing a high-dose 600,000 IU (300,000 IU/mL) in a 2 mL ampoule. It promotes intestinal calcium and phosphate absorption, supports bone mineralization, and treats severe vitamin D deficiency states like osteomalacia, rickets, hypocalcemia, osteoporosis, and malabsorption syndromes (e.g., post-bariatric surgery, chronic kidney disease).
Tell us about your requirement
Price:
Quantity
Select Unit
50
100
200
250
500
1000+
Additional detail
Mobile number
Email
Name
Comapny Name
Phone Number
Email Id
City / State
Confirm Your Requirement
Verification Code
Did not receive yet?
Resend OTP
You’re Done!
We have received your requirements and will reply shortly with the best price.
Products You May Like
More Products in Analgesic & Anti-inflammatory Drugs - Nsaids Category
Ingredients : Artesunate Injection IP 120mg (under DPCO) is a sterile lyophilized powder vial for IV/IM reconstitution, included in India's Drug Price Control Order for affordable access to essential antimalarial therapy.
It rapidly converts to dihydroartemisinin, generating free radicals that alkylate Plasmodium falciparum proteins, treating severe malaria (cerebral, multiorgan failure) in adults/children; WHO firstline for severe cases.